JP2011501176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501176A5 JP2011501176A5 JP2010530497A JP2010530497A JP2011501176A5 JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5 JP 2010530497 A JP2010530497 A JP 2010530497A JP 2010530497 A JP2010530497 A JP 2010530497A JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- inflammatory
- symptoms
- patient
- disease progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 claims description 14
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 5
- 231100000827 tissue damage Toxicity 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 208000034486 Multi-organ failure Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20070795 | 2007-10-24 | ||
| FI20070795A FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| PCT/FI2008/050576 WO2009053523A1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Division JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501176A JP2011501176A (ja) | 2011-01-06 |
| JP2011501176A5 true JP2011501176A5 (https=) | 2012-04-19 |
| JP4982610B2 JP4982610B2 (ja) | 2012-07-25 |
Family
ID=38656804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530497A Expired - Fee Related JP4982610B2 (ja) | 2007-10-24 | 2008-10-15 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100209942A1 (https=) |
| EP (2) | EP2201376B1 (https=) |
| JP (2) | JP4982610B2 (https=) |
| KR (2) | KR20100059902A (https=) |
| CA (1) | CA2702635A1 (https=) |
| CY (2) | CY1113403T1 (https=) |
| DK (2) | DK2201376T3 (https=) |
| ES (2) | ES2532361T3 (https=) |
| FI (1) | FI20070795A0 (https=) |
| HR (2) | HRP20120743T1 (https=) |
| PL (2) | PL2201376T3 (https=) |
| PT (2) | PT2201376E (https=) |
| SI (2) | SI2201376T1 (https=) |
| WO (1) | WO2009053523A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2240781T3 (en) | 2008-01-18 | 2018-03-26 | Harvard College | METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| EP2596349B1 (en) | 2010-07-23 | 2017-12-13 | President and Fellows of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| EP2596134B1 (en) | 2010-07-23 | 2020-04-08 | President and Fellows of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| WO2012012693A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| WO2013188846A1 (en) | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
| EP2861788B1 (en) | 2012-06-15 | 2018-10-10 | Progenity, Inc. | Methods of detecting diseases or conditions using circulating diseased cells |
| DK2956772T3 (en) * | 2013-02-14 | 2018-08-13 | Faron Pharmaceuticals Oy | A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| MA40636A (fr) | 2014-09-11 | 2015-09-11 | Colleen Kelly | Procédés pour détecter le cancer de la prostate |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| GB201706747D0 (en) | 2017-04-27 | 2017-06-14 | Queen Mary | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2228970A1 (en) * | 1995-08-18 | 1997-02-27 | Donald W. Landry | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| AU7310496A (en) * | 1995-10-13 | 1997-04-30 | Imperial College Of Science, Technology And Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
| HUP0002003A3 (en) * | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
| US20030099608A1 (en) * | 2001-03-27 | 2003-05-29 | Presnell Scott R. | Human cytokine receptor |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
| WO2004084933A1 (en) * | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
| CN1835962A (zh) * | 2003-06-03 | 2006-09-20 | 加利福尼亚大学董事会 | 利用乙酰化二糖治疗疾病的组合物与方法 |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| FI20051003A0 (fi) | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| WO2007107598A1 (en) * | 2006-03-21 | 2007-09-27 | Heinrich-Heine-Universität Düsseldorf | Phosphorylated a2a receptor agonists |
| EP3796002B1 (en) * | 2006-07-14 | 2023-11-22 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
-
2007
- 2007-10-24 FI FI20070795A patent/FI20070795A0/fi not_active Application Discontinuation
-
2008
- 2008-10-15 DK DK08842581.4T patent/DK2201376T3/da active
- 2008-10-15 PT PT08842581T patent/PT2201376E/pt unknown
- 2008-10-15 US US12/679,785 patent/US20100209942A1/en not_active Abandoned
- 2008-10-15 KR KR1020107006430A patent/KR20100059902A/ko not_active Ceased
- 2008-10-15 PT PT12002502T patent/PT2503338E/pt unknown
- 2008-10-15 PL PL08842581T patent/PL2201376T3/pl unknown
- 2008-10-15 SI SI200830723T patent/SI2201376T1/sl unknown
- 2008-10-15 CA CA2702635A patent/CA2702635A1/en not_active Abandoned
- 2008-10-15 SI SI200831377T patent/SI2503338T1/sl unknown
- 2008-10-15 KR KR1020167005473A patent/KR20160029869A/ko not_active Ceased
- 2008-10-15 EP EP08842581A patent/EP2201376B1/en active Active
- 2008-10-15 ES ES12002502.8T patent/ES2532361T3/es active Active
- 2008-10-15 DK DK12002502T patent/DK2503338T3/en active
- 2008-10-15 PL PL12002502T patent/PL2503338T3/pl unknown
- 2008-10-15 ES ES08842581T patent/ES2389751T3/es active Active
- 2008-10-15 WO PCT/FI2008/050576 patent/WO2009053523A1/en not_active Ceased
- 2008-10-15 JP JP2010530497A patent/JP4982610B2/ja not_active Expired - Fee Related
- 2008-10-15 HR HRP20120743AT patent/HRP20120743T1/hr unknown
- 2008-10-15 EP EP12002502.8A patent/EP2503338B1/en active Active
-
2012
- 2012-04-23 JP JP2012098081A patent/JP5619810B2/ja not_active Expired - Fee Related
- 2012-10-04 CY CY20121100924T patent/CY1113403T1/el unknown
-
2015
- 2015-02-16 HR HRP20150181TT patent/HRP20150181T1/hr unknown
- 2015-03-06 CY CY20151100234T patent/CY1116089T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501176A5 (https=) | ||
| Martinez et al. | Idiopathic pulmonary fibrosis | |
| Meyer | Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis | |
| Nadeem et al. | Serum inflammatory markers in obstructive sleep apnea: a meta-analysis | |
| Agassandian et al. | C-reactive protein and lung diseases | |
| Paplińska et al. | Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients | |
| Aleem et al. | Correlation of C-reactive protein levels with severity of chronic urticaria | |
| Olczak et al. | Elevated serum and urine levels of progranulin (PGRN) as a predictor of microglia activation in the early phase of traumatic brain injury: a further link with the development of neurodegenerative diseases | |
| Zeng et al. | Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis | |
| JP2015503106A5 (https=) | ||
| Sandri et al. | Transcriptomic, translatomic, and proteomic profiling platform discovers a physiological hallmark of COPD-associated lung cancer | |
| Parvanescu et al. | Gout-risks, comorbidities and associations | |
| Orlova et al. | Extrinsic interstitial lung disease activity markers | |
| Sunadome et al. | Associations between blood eosinophil counts and body mass index, lung function and genetic polymorphisms in the general population: The Nagahama Study | |
| Niaz et al. | Association of serum resistin with lipids in hypertensives and coronary artery disease patients | |
| Belal et al. | Pentraxin 3 is Increased Early in Blood of Patients with Cerebral Stroke and Predicts its Severity. | |
| Sema et al. | Measurement of avian antigen in household dust for management of chronic bird-related hypersensitivity pneumonitis | |
| Cruz Rivera et al. | An Early SYK Stop: Novel Frameshift Mutation in a Case of Neutrophilic Asthma | |
| Shin et al. | The Serum C-reactive Protein And Alpha 1-antitrypsin Levels Of Retired Workers Exposed To Inorganic Dusts In Korea | |
| Sandri et al. | A75 BIG AND BIGGER (DATA): OMICS AND BIOMARKERS OF LUNG DISEASES: Transcriptomic, Translatomic, And Proteomic Profiling Platform Discovers A Physiological Hallmark Of COPD-Associated Lung Cancer | |
| Scarpa et al. | Autophagy, Apoptosis, Cell Proliferation And Ceramide Expression In Lung Parenchyma Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | |
| EP1848997A4 (en) | COMPOSITION FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF OBSTRUCTIVE CHRONIC BRONCHO PNEUMOPATHY (COPD) | |
| Yatera et al. | High incidence of sinusitis in asthmatic patients detected by computed tomography | |
| Zhang et al. | D41 COPD: BIOMARKERS IN STABLE DISEASE AND EXACERBATIONS: Increased Serum Levels Of Lipocalin 1 And 2 In Patients With Stable Chronic Obstructive Pulmonary Disease | |
| Scarpa et al. | Increased Ceramide Expression In Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD) And Idiopathic Pulmonary Fibrosis (IPF) |